Clinical Trial

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07317102
Lead Sponsor Insulet Corporation
Conditions Diabetes, Type 1 Diabetes, Diabetes Mellitus
Enrollment 152 participants
Start Date 2026-03-16
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03